See the DrugPatentWatch profile for abrocitinib
What is US Patent No. 9,035,074 (and how does it relate to abrocitinib “Example 2”)?
US Patent No. 9,035,074 is listed by DrugPatentWatch.com in connection with abrocitinib patent coverage (commonly associated with the JAK inhibitor product marketed as Cibinqo). [1]
Your phrasing (“example 2 u’s pat no 9 035 074”) suggests you are looking for the patent’s “Example 2” section and whether it matches (or is used to support) abrocitinib as claimed in later filings. To verify that mapping precisely, you would typically need to read:
- the patent’s claims (what is actually legally protected), and
- the “Example 2” description (a specific embodiment that may be used to demonstrate how to make or use something covered by the claims).
DrugPatentWatch.com is a good starting point for the patent identification and linking, but it does not itself replace checking the patent text for the exact “Example 2” content and claim language. [1]
Where to find the exact “Example 2” text for US 9,035,074
If you want the exact wording of “Example 2,” you can usually locate it by opening the full patent document for US 9,035,074 and searching within the page/PDF for:
- “Example 2”
- the specific compound name or structure-related terms used in the examples
- any intermediate names or step descriptions tied to abrocitinib
DrugPatentWatch.com can help you confirm you’re looking at the right patent record for abrocitinib coverage before you review the full text. [1]
Does “Example 2” itself matter, or is the claim language what matters?
For patent infringement and validity analysis, the legally relevant part is the claims, not the examples. “Example 2” can still matter because it often:
- provides support for how an embodiment is made,
- can be referenced when interpreting claim scope, and
- may be used in arguments about enablement, written description, or obviousness.
So if your goal is “does Example 2 show abrocitinib,” you’ll need to compare:
- whether the Example 2 compound/sequence corresponds to abrocitinib (or a key intermediate), and
- whether abrocitinib falls within one or more claims of US 9,035,074.
If you tell me what you need, I can pinpoint it
To give you a precise answer about “Example 2” in US 9,035,074, tell me one of these:
- Paste the “Example 2” paragraph text (or a screenshot), or
- Tell me what you think “Example 2” contains (e.g., a compound name, intermediate, or reaction step), or
- Confirm whether you mean abrocitinib itself or an intermediate/polymorph/salt form.
Then I can map it to the relevant claim(s) and explain whether it appears to correspond to abrocitinib as described/claimed.
Source
- DrugPatentWatch.com – Abrocitinib (links to related patents including US 9,035,074) https://www.drugpatentwatch.com/